ONC (BeOne Medicines) Growth Rank: 8 (As of Aug. 23, 2026) — 14% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONC BeOne Medicines Ltd ONC
79 GF Score
Price $374.47
GF Value $376.48
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Growth Rank?

BeOne Medicines ONC +1.44% 79 Growth Rank is 8 as of Aug. 23, 2026, which is 14% above its 10-year median of 7.00. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $376.48 (Fairly Valued). The stock has 5 warning signs investors should review.

BeOne Medicines has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

BeOne Medicines Growth Rank Related Terms

ONC vs ALNY, RVMD, RPRX: Growth Rank Comparison

For the Biotechnology subindustry, BeOne Medicines's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Growth Rank distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Growth Rank falls into.


ONC
79GF Score
BeOne Medicines Ltd ONC
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
BeOne Medicines (ONC) has a Growth Rank of 8 as of Aug. 23, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on BeOne Medicines and its competitors. This is 14% above median its historical median of 7.00. Over the past decade, BeOne Medicines' Growth Rank has ranged from 3.00 to 10.00.
Is BeOne Medicines' Growth Rank too high?
BeOne Medicines' current Growth Rank of 8 is 14% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Growth Rank compare to ALNY and RVMD?
BeOne Medicines' Growth Rank of 8 can be compared against companies in the Biotechnology industry. Historically, BeOne Medicines' own Growth Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Growth Rank is 8, which is 14% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $376.48, compared to a current price of $374.47 — trading 0.5% below its estimated fair value. The current Growth Rank is 8, which is 14% above median its 10-year median of 7.00. BeOne Medicines' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Growth Rank is 8 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $374.47 is trading 0.5% below its estimated GF Value™ of $376.48. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for ONC:

  • Growth Rank: 8 (14% above median its 10-year median of 7.00)
  • GF Value™: $376.48 vs. price of $374.47 (0.5% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score

Get the complete analysis for ONC

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$374.47
Price
$376.48
GF Value